Brokerages Set ICU Medical, Inc. (NASDAQ:ICUI) Price Target at $177.25

ICU Medical, Inc. (NASDAQ:ICUI) has received an average rating of “Moderate Buy” from the four research firms that are covering the company, Marketbeat reports. One analyst has rated the stock with a hold rating and three have assigned a buy rating to the company. The average 12 month price target among analysts that have updated their coverage on the stock in the last year is $199.67.

A number of analysts recently commented on the stock. KeyCorp boosted their target price on shares of ICU Medical from $198.00 to $209.00 and gave the stock an “overweight” rating in a report on Wednesday, November 13th. Jefferies Financial Group raised ICU Medical from a “hold” rating to a “buy” rating and set a $200.00 price target on the stock in a report on Wednesday, December 11th. Needham & Company LLC reissued a “hold” rating on shares of ICU Medical in a research note on Wednesday, November 13th. StockNews.com upgraded ICU Medical from a “hold” rating to a “buy” rating in a report on Wednesday, November 20th. Finally, Raymond James upped their target price on ICU Medical from $158.00 to $190.00 and gave the company an “outperform” rating in a report on Thursday, September 12th.

Insiders Place Their Bets

In related news, CEO Vivek Jain sold 12,000 shares of the business’s stock in a transaction on Tuesday, October 1st. The shares were sold at an average price of $178.46, for a total transaction of $2,141,520.00. Following the transaction, the chief executive officer now owns 104,593 shares of the company’s stock, valued at approximately $18,665,666.78. The trade was a 10.29 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director David C. Greenberg sold 972 shares of the firm’s stock in a transaction on Wednesday, November 27th. The stock was sold at an average price of $158.11, for a total transaction of $153,682.92. Following the completion of the sale, the director now owns 5,037 shares in the company, valued at $796,400.07. This represents a 16.18 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 40,364 shares of company stock valued at $6,869,878 in the last quarter. Insiders own 6.70% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the business. CWM LLC increased its stake in shares of ICU Medical by 18.5% in the 2nd quarter. CWM LLC now owns 767 shares of the medical instruments supplier’s stock valued at $91,000 after buying an additional 120 shares during the period. SG Americas Securities LLC grew its holdings in shares of ICU Medical by 441.7% in the 2nd quarter. SG Americas Securities LLC now owns 5,818 shares of the medical instruments supplier’s stock valued at $691,000 after buying an additional 4,744 shares during the period. Blue Trust Inc. increased its position in shares of ICU Medical by 384.4% in the 2nd quarter. Blue Trust Inc. now owns 1,090 shares of the medical instruments supplier’s stock valued at $129,000 after buying an additional 865 shares in the last quarter. Nisa Investment Advisors LLC raised its stake in ICU Medical by 3.2% during the 2nd quarter. Nisa Investment Advisors LLC now owns 10,939 shares of the medical instruments supplier’s stock worth $1,299,000 after buying an additional 339 shares during the period. Finally, Kirr Marbach & Co. LLC IN lifted its holdings in ICU Medical by 5.6% during the second quarter. Kirr Marbach & Co. LLC IN now owns 23,809 shares of the medical instruments supplier’s stock worth $2,827,000 after acquiring an additional 1,269 shares in the last quarter. Institutional investors and hedge funds own 96.10% of the company’s stock.

ICU Medical Trading Down 2.4 %

Shares of NASDAQ:ICUI opened at $161.64 on Friday. The company has a 50 day moving average of $171.12 and a 200-day moving average of $151.65. The company has a current ratio of 2.29, a quick ratio of 1.03 and a debt-to-equity ratio of 0.75. The firm has a market cap of $3.96 billion, a P/E ratio of -35.37 and a beta of 0.62. ICU Medical has a twelve month low of $86.80 and a twelve month high of $196.26.

About ICU Medical

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.